Talk about niche target-marketing to hypochondriacs and Teh Coof-obsessesed.
UPI: FDA authorizes first at-home test to detect both flu and COVID-19.
The Lucira test will be sold over-the-counter and it can detect both Influenza A and Influenza B, as well as the SARS-CoV-2 virus - the virus that causes COVID-19, FDA officials announced Friday in a news release.
The announcement marks a breakthrough as the first at-home test for flu, the Washington Post reported. Testing for the flu previously required a visit to a doctor's office or urgent care clinics.
Will a majority of people make a mad-dash, rushing to test themselves the moment they sneeze or have a runny nose? Probably, based on the number of past, current and "I plan to take all future Coof Boosters" Jab Addicts and Mask-Karens.
Lucira. The FDA approved an at-home test from a company whose stock closed on Friday at .14 cents, whose all-time high of $37/share was two years ago and their 52W high is $5.67? Oh, yeah - full faith and trust, BAYBEE!
It might be a worth a look as a short-term buy-hold-sell when or if it hits "dollars." (This is not presented or intended in any way as financial or investment advice.*)
If I felt energetic, I'd search who the big buyers and investors of Lucira stock are the past 30-90 days. I wonder if Paul "The Hammer" Pelosi, Sr. or other spouses of politicians sank some $$$$$ into this Pharma Company?
With a 52W low of .04 cents, Lucira badly needed a Booster product. I wonder how many palms at the FDA and TPTB were greased? It'd be great if this product failed.
* DISCLAIMER: Lucira stock assessment is purely speculative. It is NOT financial advice. Author assumes no risk, responsibility and/or liability for any financial losses. Immediately seek trained health professionals if you have the slightest inclination rolling dice with your financial risk based on anything written anywhere on this blog.
No comments:
Post a Comment